Phase 3 cardiovascular outcomes trial of Zilebesiran
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs Zilebesiran (Primary)
- Indications Hypertension
- Focus Registrational; Therapeutic Use
- 15 Jan 2025 New trial record
- 12 Jan 2025 According to Alnylam Pharmaceuticals media release, company plans to initiate a Phase 3 cardiovascular outcomes trial in the second half of 2025.